Cellarcus Biosciences

Executive Summary

Cellarcus Biosciences is a privately held biotechnology company based in Cambridge, Massachusetts, specializing in standardized tools for extracellular vesicle (EV) analysis. Founded in 2019, the company addresses a critical bottleneck in EV research and diagnostics by providing quantitative, reproducible measurements of EV size, concentration, and cargo directly from complex biofluids such as plasma and serum, without requiring biased enrichment steps. Its core product offerings—vFC™ assay kits, vCal™ calibration standards, and vTag™ antibodies—are designed to work on standard flow cytometers, enabling widespread adoption in academic, clinical, and pharmaceutical laboratories. By eliminating variability in EV characterization, Cellarcus positions itself as an enabler of reproducible biomarker discovery and therapeutic development, particularly in oncology, neurology, and inflammatory diseases. Despite its innovative platform, Cellarcus remains at an early commercial stage with limited public information on funding or partnerships. The company's technology has the potential to become an industry standard for EV analysis, but it faces competition from other EV characterization methods and the need for broader market adoption. Near-term growth will depend on securing strategic collaborations, expanding its product portfolio, and demonstrating clinical utility. With the EV field gaining traction in liquid biopsy and drug delivery, Cellarcus is well-positioned to capitalize on the trend, though execution and market penetration remain key risks.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Strategic Partnership with a Major Diagnostics or Pharma Company60% success
• Q4 2026Launch of a New Product for a Specific Disease Indication (e.g., Cancer Liquid Biopsy)50% success